The Application, Challenges, and Advancement Toward Regulatory Acceptance of Digital Toxicologic Pathology: Results of the 7th ESTP International Expert Workshop (September 20-21, 2019).

digital pathology good laboratory practice nonclinical regulatory toxicologic pathology validation whole slide imaging

Journal

Toxicologic pathology
ISSN: 1533-1601
Titre abrégé: Toxicol Pathol
Pays: United States
ID NLM: 7905907

Informations de publication

Date de publication:
06 2021
Historique:
pubmed: 11 12 2020
medline: 11 12 2020
entrez: 10 12 2020
Statut: ppublish

Résumé

With advancements in whole slide imaging technology and improved understanding of the features of pathologist workstations required for digital slide evaluation, many institutions are investigating broad digital pathology adoption. The benefits of digital pathology evaluation include remote access to study or diagnostic case materials and integration of analysis and reporting tools. Diagnosis based on whole slide images is established in human medical pathology, and the use of digital pathology in toxicologic pathology is increasing. However, there has not been broad adoption in toxicologic pathology, particularly in the context of regulatory studies, due to lack of precedence. To address this topic, as well as practical aspects, the European Society of Toxicologic Pathology coordinated an expert international workshop to assess current applications and challenges and outline a set of minimal requirements needed to gain future regulatory acceptance for the use of digital toxicologic pathology workflows in research and development, so that toxicologic pathologists can benefit from digital slide technology.

Identifiants

pubmed: 33297858
doi: 10.1177/0192623320975841
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

720-737

Auteurs

Vanessa L Schumacher (VL)

1529Roche Innovation Center Basel, Pharma Research and Early Development, F. Hoffmann-La Roche, Ltd, Basel, Switzerland.

Famke Aeffner (F)

Amgen Inc, Amgen Research, Translational Safety and Bioanalytical Sciences, South San Francisco, CA, USA.

Catherine Botteron (C)

Sirius Pathology, Cruseilles, France.

Jonathan Carter (J)

63899Covance Laboratories, Harrogate, United Kingdom.

Laëtitia Elies (L)

72810Bayer Crop Science Division, Sophia Antipolis, France.
25913Charles River Laboratories, Lyon, France.

Jeffery A Engelhardt (JA)

448132Ionis Pharmaceuticals Inc, Carlsbad, CA, USA.

Pierluigi Fant (P)

25913Charles River Laboratories, Lyon, France.

Thomas Forest (T)

Merck & Co, Inc, West Point, Pennsylvania, USA.

Peter Hall (P)

35932UCB Pharma, Slough, United Kingdom.

Deon Hildebrand (D)

1929GlaxoSmithKline, Ware, United Kingdom.

Robert Klopfleisch (R)

9166Freie Universitaet Berlin, Institute of Veterinary Pathology, Berlin, Germany.

Thomas Lucotte (T)

56511Agence nationale de sécurité du médicament et des produits de santé (ANSM), Saint-Denis, France.

Heike Marxfeld (H)

5184BASF SE, Ludwigshafen, Germany.

LuAnn Mckinney (L)

4137US Food and Drug Administration, Silver Spring, MD, USA.

Pierre Moulin (P)

Novartis, Basel, Switzerland.

Elizabeth Neyens (E)

Elizabethtoxpath Consulting Inc, Vancouver, British Columbia, Canada.

Xavier Palazzi (X)

Pfizer, Groton, CT, USA.

Alain Piton (A)

ALP Quality Systems, Sophia Antipolis, France.

Elena Riccardi (E)

402057IDEXX Laboratories Ltd, Wetherby, United Kingdom.

Daniel R Roth (DR)

69479Swissmedic, Bern, Switzerland.

Justin D Vidal (JD)

Charles River, Mattawan, MI, USA.

Bethany Williams (B)

572272Department of Histopathology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom.

Classifications MeSH